Semaglutide for Weight Loss: The Complete Evidence Guide

Semaglutide has become one of the most talked-about compounds in modern medicine — and for good reason. The clinical trial data is some of the strongest I've seen for any weight loss intervention. But between the brand-name hype, the compounding market, and the questions people aren't asking their doctors, there's a lot to untangle.

Here's everything I know, with the citations to back it up.

What semaglutide actually is

Semaglutide is a GLP-1 receptor agonist — a synthetic analog of glucagon-like peptide-1, a hormone your gut releases after eating. GLP-1 does several things: it stimulates insulin release, suppresses glucagon, slows gastric emptying, and — critically for weight loss — acts on appetite centers in the brain to reduce hunger and food intake.

Originally developed for type 2 diabetes (marketed as Ozempic at lower doses), semaglutide at 2.4mg weekly was approved by the FDA in 2021 specifically for chronic weight management under the brand name Wegovy.

What the STEP trials actually showed

The STEP (Semaglutide Treatment Effect in People with obesity) trial program is one of the strongest evidence bases for any weight loss drug ever studied. Here's what the key trials found:

• STEP 1 (68 weeks, n=1,961): Average weight loss of 14.9% of body weight on semaglutide 2.4mg vs. 2.4% on placebo. About 1 in 3 participants lost ≥20% of body weight.
• STEP 2 (68 weeks, adults with T2D): 9.6% weight loss vs. 3.4% on placebo — somewhat lower, consistent with how diabetes affects weight loss response.
• STEP 3: Added intensive behavioral therapy — weight loss improved to 16%, highlighting that lifestyle still matters alongside medication.
• STEP 4: When people who had lost weight stopped taking semaglutide, they regained about two-thirds of the weight within a year. This is the data point nobody talks about enough.

The SELECT trial (2023) added something significant: in people with cardiovascular disease but without diabetes, semaglutide reduced major cardiovascular events by 20%. This moved it from "weight loss drug" to something with broader cardiometabolic implications.

Compounded semaglutide — what you need to know

During the Wegovy shortage, the FDA allowed compounding pharmacies to produce semaglutide. This opened a market that still exists even as supply constraints have eased, because compounded versions are significantly cheaper.

What's worth knowing:

• Compounded semaglutide is not FDA-approved and hasn't gone through the same manufacturing quality controls as branded versions.
• Some compounders use semaglutide base (not the salt form used in Ozempic/Wegovy), which may have different bioavailability — the clinical significance of this is debated.
• Quality varies dramatically between compounding pharmacies. A 503B outsourcing facility is held to higher standards than a typical 503A pharmacy compounding for individual prescriptions.
• The FDA has flagged adverse events associated with compounded semaglutide, including dosing errors from unit confusion.

If cost is the barrier to branded semaglutide, compounded from a reputable 503B facility with physician oversight is a reasonable discussion to have. If someone is selling it to you without a prescription, that's a different situation entirely.

Side effects — the honest version

The most common side effects are GI-related: nausea, vomiting, diarrhea, and constipation. These are typically worst during dose escalation and improve over time. In the STEP trials, about 4-7% of participants discontinued due to GI side effects.

The more serious concerns worth discussing with your physician:

• Muscle loss: A significant portion of weight lost on GLP-1s is lean mass, not just fat. Resistance training and adequate protein intake appear to mitigate this.
• Pancreatitis: A rare but documented risk. History of pancreatitis is a contraindication.
• Thyroid C-cell tumors: Seen in rodent studies at high doses. A black box warning exists, though human risk appears low. Contraindicated with personal or family history of medullary thyroid carcinoma or MEN2.
• Gallbladder issues: Rapid weight loss increases gallstone risk with any method, including GLP-1s.

5 questions to ask your doctor before starting

I wrote a separate piece on this, but the short version: ask about your cardiovascular history, whether the dose escalation schedule is right for you, what monitoring they recommend, their thoughts on muscle preservation, and the long-term plan if you want to eventually come off.

My take

Semaglutide is genuinely one of the most effective weight loss interventions we've ever had in medicine. The trial data is real, the cardiometabolic benefits are real, and for many people it addresses something that diet and exercise alone haven't been able to budge.

But it's a medication that works while you're taking it, requires physician oversight, has real side effects, and doesn't replace the lifestyle factors that determine long-term health. Anyone framing it as an easy solution is leaving out important context.

Key references

• Wilding JPH, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM, 384(11), 989-1002.
• Lincoff AM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM, 389(24), 2221-2232.
• Rubino DM, et al. (2022). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA, 327(14), 1414-1425.